Physician profile
Ronald M Gabor
NPI 1184611642
$2,531.97
in general payments reported to CMS, 2019-2025
17 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $167 · 2021: $180 · 2022: $369 · 2023: $906 · 2024: $266 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $544.19 | 2023-2025 | Ffrct |
| Boston Scientific Corporation | $458.84 | 2019-2023 | Watchman Flx, Watchman Access System, Watchman |
| Astellas Pharma US INC | $374.99 | 2021-2022 | |
| Novo Nordisk INC | $176.00 | 2023-2025 | Ozempic, Wegovy |
| Impulse Dynamics (USA) INC. | $169.81 | 2023-2025 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.12 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $129.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $124.56 | 2020 | |
| Pfizer INC. | $69.87 | 2019-2023 | |
| Amgen INC. | $68.94 | 2019-2023 | Repatha |
| Genentech USA, INC. | $67.49 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.39 | 2019-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.03 | 2022-2024 | Lifevest |
| Philips North America LLC | $42.93 | 2023 | |
| Lilly USA, LLC | $24.01 | 2025 | Zepbound, Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $20.55 | 2023 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $18.55 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Gabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.